The impact of a prior malignancy on outcomes in gastric cancer patients
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.3722
Abstract: The number of cancer survivors has increased rapidly, and there is a higher risk of developing a second cancer. Whether a prior malignancy could affect survival outcomes is unknown. We aimed to investigate the clinical… read more here.
Keywords: malignancy outcomes; gastric cancer; prior malignancy; cancer ... See more keywords
Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide
Sign Up to like & getrecommendations! Published in 2017 at "Medical Oncology"
DOI: 10.1007/s12032-017-1060-9
Abstract: The objective of this study was to investigate the impact of prior treatment with androgen receptor-axis-targeted (ARAT) agents, abiraterone acetate (AA) and enzalutamide (Enz), on the activity of subsequently introduced docetaxel in patients with metastatic… read more here.
Keywords: psa; impact; receptor axis; androgen receptor ... See more keywords
Impact of prior sternotomy on survival and allograft function after heart transplantation: A single center matched analysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cardiac Surgery"
DOI: 10.1111/jocs.16224
Abstract: Orthotopic heart transplantation (OHT) remains the gold standard for the treatment of end‐stage heart failure. The number of patients who have had at least one prior sternotomy while awaiting transplantation has increased over the years… read more here.
Keywords: heart; impact prior; heart transplantation; prior sternotomy ... See more keywords
The impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.3_suppl.247
Abstract: 247Background: It is unclear whether prior treatment with ramucirumab (RAM) or RAM plus paclitaxel (PAC), standard second-line treatments for metastatic gastric or gastroesophageal junction cancer ... read more here.
Keywords: therapies outcomes; prior therapies; impact prior; outcomes trifluridine ... See more keywords